1. Home
  2. RCUS vs EMBC Comparison

RCUS vs EMBC Comparison

Compare RCUS & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • EMBC
  • Stock Information
  • Founded
  • RCUS 2015
  • EMBC 1924
  • Country
  • RCUS United States
  • EMBC United States
  • Employees
  • RCUS N/A
  • EMBC N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • EMBC Medical/Dental Instruments
  • Sector
  • RCUS Health Care
  • EMBC Health Care
  • Exchange
  • RCUS Nasdaq
  • EMBC Nasdaq
  • Market Cap
  • RCUS 1.2B
  • EMBC 1.0B
  • IPO Year
  • RCUS 2018
  • EMBC N/A
  • Fundamental
  • Price
  • RCUS $11.07
  • EMBC $14.10
  • Analyst Decision
  • RCUS Buy
  • EMBC Buy
  • Analyst Count
  • RCUS 11
  • EMBC 2
  • Target Price
  • RCUS $31.11
  • EMBC $19.00
  • AVG Volume (30 Days)
  • RCUS 1.1M
  • EMBC 397.0K
  • Earning Date
  • RCUS 02-25-2025
  • EMBC 02-06-2025
  • Dividend Yield
  • RCUS N/A
  • EMBC 4.16%
  • EPS Growth
  • RCUS N/A
  • EMBC 2.96
  • EPS
  • RCUS N/A
  • EMBC 0.99
  • Revenue
  • RCUS $263,000,000.00
  • EMBC $1,107,700,000.00
  • Revenue This Year
  • RCUS $127.65
  • EMBC $0.26
  • Revenue Next Year
  • RCUS N/A
  • EMBC $1.24
  • P/E Ratio
  • RCUS N/A
  • EMBC $14.56
  • Revenue Growth
  • RCUS 119.17
  • EMBC N/A
  • 52 Week Low
  • RCUS $10.63
  • EMBC $9.93
  • 52 Week High
  • RCUS $20.31
  • EMBC $21.48
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 34.34
  • EMBC 22.61
  • Support Level
  • RCUS $10.63
  • EMBC $14.55
  • Resistance Level
  • RCUS $13.49
  • EMBC $15.72
  • Average True Range (ATR)
  • RCUS 0.77
  • EMBC 0.91
  • MACD
  • RCUS -0.13
  • EMBC -0.33
  • Stochastic Oscillator
  • RCUS 13.88
  • EMBC 6.28

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: